COVID-19 Vaccine Timing-Routine Schedule



Age*	Vaccine	If unvaccinated:	If had monovalent doses give bivalent (B) doses:
6 months- 4 years	Pfizer– Infant/Toddler Bivalent	1st 3-8 2nd ≥8 weeks Dose Dose	If 1 prior dose, then: 3-8** weeks B ≥8 weeks B If 2-3 prior doses, then: ≥8 weeks B
6 months– 5 years	Moderna – Bivalent	1st 4-8 2nd Dose Use blue cap vial, 0.25mL	If 1 prior dose, then^: 4-8** weeks B Blue cap, 0.25mL If 2 prior doses then^: ≥2 months B Pink cap, 0.2mL
6 + years®	Moderna – Bivalent	1 ≥4 Ages 65+ optional 2nd bivalent dose (Moderna/Pfizer) Use blue cap vial, 6-11years: 0.25mL, 12+ years: 0.5mL	
5 –11 years [†]	Pfizer – Pediatric Bivalent	1 Dose	If 1 or more prior doses (of any of the 4 brands), then [†] : ≥2 months Bivalent (Moderna/Pfizer) (Ages 65+ may receive 1 additional bivalent dose ≥4 months after 1st)
12+ years	Pfizer/ Adol/Adult Bivalent	1 ≥4 Ages 65+ optional 2nd bivalent dose (Moderna/Pfizer)	
12+ years	Novavax [‡] Monovalent	1st 3-8 2nd Dose	
18+ years	Janssen (J&J) Monovalent Expired	Dose given before expiration	

- * See CDC recommendations for children transitioning from a younger to older age group
- ** An <u>8-week interval</u> may be preferable for some people, especially for males 12-39 years.
- ß Please note the Moderna bivalent dosages differ for ages 6-11 (0.25 mL, 25 mcg) and 12+ (0.5 mL, 50 mcg) years.
- ^ Children 5 years of age who had 1 or more doses of Moderna monovalent vaccine may receive Moderna or Pfizer bivalent vaccine.
- † Children 5 years of age who had 1 or more doses of Pfizer monovalent vaccine are only eligible to receive Pfizer bivalent vaccine.
- ‡ People 18+ years who have not received any booster doses and are unable or unwilling to receive a bivalent booster, may receive the monovalent Novavax booster as a single booster dose at least 6 months after their primary series.

View Interim Clinical Considerations for Use of COVID-19 Vaccines for details. Schedule is subject to change.

COVID-19 Vaccine Timing if Moderately/Severely Immunocompromised



Children and Adolescents (Ages 6 months-17 years)

Age	Vaccine	If unvaccinated* [§] :	If had prior monovalent doses give bivalent (B) doses*5:
6 months- 4 years	Pfizer Bivalent– Infant/ Toddler	1st 3 2nd ≥8 Weeks Dose weeks Dose months Optional Dose*	1 Monovalent 3 w B ≥8 w B 2-3 Monovalent ≥8 w B ≥2 m Optional Dose*
5 –11 years	Pfizer Bivalent– Pediatric	1st 3 2nd ≥4 weeks Dose weeks Dose months Dose*	1 Monovalent [†] 3 w B ≥4 w B Optional Dose*
12+ years	Pfizer Bivalent– Adol/Adult	Use orange cap for 5-11 years and gray cap for 12+ years.	3 Monovalent [†] ≥8 w B Orange cap: 5-11 yrs, Gray cap: 12+ yrs
6+ months	Moderna Bivalent	1st 4 2nd ≥4 weeks Dose Dose Months Dose* Use blue cap vial, 6 months-11years: 0.25mL, 12+ years: 0.5mL	1
12+ years	Novavax Monovalent	1st 3 2nd Dose Dose	If 1 or 2 prior doses, then: ≥8 weeks Bivalent (Moderna/Pfizer) Dose* (Moderna/Pfizer)


- * An **optional dose** may be given ≥ 2 months after the last dose. **Further doses** may be given at the healthcare provider's discretion. See <u>Table 2</u> for vial and dosage.
- § Heterologous "mix-and-match" dosing is allowed for ages 6 years and older.
- † Children 5 years of age who had 1 or more doses of Pfizer monovalent vaccine are only eligible to receive Pfizer bivalent vaccine.
- ^ Children 5 years of age who had 1 or more doses of Moderna monovalent vaccine may receive Moderna or Pfizer bivalent vaccine.

View Interim Clinical Considerations for Use of COVID-19 Vaccines for details. Schedule is subject to change.

COVID-19 Vaccine Timing if Moderately/Severely Immunocompromised



Adults (Ages 18 years and older)



- * An optional dose may be given ≥2 months after the last dose. Further doses may be given at the healthcare provider's discretion. See <u>Table 2</u> for vial and dosage.
- § Heterologous "mix-and-match" dosing is allowed for ages 6 years and older.
- ‡ People 18+ years who have not received any booster doses and are unable or unwilling to receive a bivalent booster, may receive the monovalent Novavax booster as a single booster dose at least 6 months after their primary series.

View Interim Clinical Considerations for Use of COVID-19 Vaccines for details. Schedule is subject to change.